Semaglutide Plateau in Houston: Why It Happens & the Fix

The landmark STEP 1 clinical trial (Wilding et al. NEJM 2021) tested once-weekly semaglutide 2.4 mg (Wegovy) against placebo in 1,961 adults with obesity. Participants lost an average of 14.9% of body weight over 68 weeks, but that loss was not linear. Data from the STEP trials consistently show that the most rapid weight loss occurs in the first 16-20 weeks, after which the rate of loss slows and many patients experience a plateau around weeks 28-40 before potentially resuming modest losses.

Importantly, STEP 4 (Rubino et al. JAMA 2021) demonstrated that patients who continued semaglutide after week 20 maintained significantly more weight loss than those switched to placebo, confirming that the medication remains active even when the scale stalls. Houston physicians note this is a critical distinction: a plateau does not mean semaglutide has stopped working. It often means the body has adapted and the treatment plan needs recalibration, not abandonment.

Semaglutide works by mimicking GLP-1, a gut hormone that suppresses appetite, slows gastric emptying, and improves insulin sensitivity. Over time, your body undergoes metabolic adaptation, a well-documented phenomenon where resting metabolic rate (RMR) decreases as body weight falls, requiring fewer calories to maintain the new, lower weight. This is not a semaglutide-specific flaw; it is a universal feature of significant weight loss.

Houston's climate and lifestyle patterns play a role. Brutally hot summers, often 95°F+ with high humidity from June through September, can derail the outdoor exercise habits patients build in spring. Reduced physical activity lowers total daily energy expenditure, which can tip the caloric balance just enough to stall the scale. Physicians in Katy and Pearland also frequently cite high-sodium restaurant dining and social eating culture in Greater Houston as factors that contribute to water retention and apparent plateaus even when fat loss is still occurring. Understanding the difference between a true fat-loss plateau and temporary weight fluctuation is an important first conversation to have with your prescribing physician.

Semaglutide (Wegovy) is titrated on a structured schedule: 0.25 mg weekly for weeks 1-4, increasing every four weeks up to the maintenance dose of 2.4 mg. If a patient plateaus before reaching 2.4 mg, the most straightforward clinical intervention is completing the titration to the full maintenance dose, provided tolerability allows.

For patients already at 2.4 mg, Houston-area physicians emphasize that dose escalation beyond the FDA-approved ceiling is not an evidence-supported option. Instead, the focus shifts to addressing factors that limit the medication's effectiveness. Some clinics in The Woodlands and Cypress are also evaluating patients for a transition to tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al. NEJM 2022) showed tirzepatide achieved up to 22.5% mean body weight reduction at 72 weeks, meaningfully higher than semaglutide's STEP 1 outcomes, making it a clinically reasonable escalation pathway for appropriate candidates. Always discuss medication changes with a board-certified physician, never adjust doses independently.

When a plateau hits, Houston physicians universally recommend a structured reassessment of nutrition and physical activity before any medication change. On the dietary side, the most common culprits identified at local clinics include caloric creep (underestimating portion sizes after appetite suppression normalizes), insufficient protein intake, and high-carbohydrate meals at popular Houston Tex-Mex and BBQ restaurants. Physicians typically recommend a protein target of 1.2-1.6 g per kg of goal body weight to preserve lean muscle mass during GLP-1-assisted weight loss.

For exercise, guidance from the American College of Sports Medicine recommends 150-300 minutes of moderate-intensity aerobic activity weekly for weight maintenance, and more for active weight loss. Resistance training is particularly important, as semaglutide-driven weight loss includes some lean mass reduction. Houston has strong options for supervised fitness, including medical fitness programs affiliated with Houston Methodist and Memorial Hermann, as well as community walking trails at Terry Hershey Park (Katy), Exploration Green (Clear Lake), and the Woodlands Waterway. Patients in Pearland and Sugar Land have access to multiple YMCA locations with medically oriented fitness classes. Pairing exercise recalibration with a dietitian consult, often available through the same clinic prescribing your semaglutide, is the recommended gold standard.

Greater Houston is one of the most economically and professionally demanding metro areas in the country. Energy-sector schedules, long commutes on I-10 and the Beltway, and the stress of hurricane season preparedness all contribute to elevated cortisol levels that are directly linked to weight loss resistance. Chronic stress elevates cortisol, which promotes fat storage, particularly visceral abdominal fat, and can blunt the appetite-suppressing effects of GLP-1 receptor agonists.

Physicians at physician-supervised weight loss clinics across Houston increasingly incorporate behavioral health support as a core component of plateau management. This may include referral to a licensed clinical psychologist or therapist specializing in health behavior change, structured sleep hygiene intervention (poor sleep independently impairs weight loss and increases hunger hormones like ghrelin), and mindful eating programs. The STEP 1 trial's lifestyle intervention arm included 500 kcal/day deficit counseling plus physical activity guidance, underlining that behavioral support is embedded in the clinical evidence, not optional. Patients should proactively ask their Houston clinic whether behavioral health referrals are part of their plateau protocol.

Understanding the cost of semaglutide in the context of a plateau, when patients may feel they're not getting their money's worth, is a real and valid concern for Houston-area families. Wegovy's list price without insurance remains approximately $1,350-$1,400/month as of early 2026. Major Texas carriers including Blue Cross Blue Shield of Texas, Aetna Texas, UnitedHealthcare, and Cigna have variable formulary coverage for Wegovy and Ozempic (labeled for type 2 diabetes) that has evolved rapidly.

For patients hitting a plateau and considering a switch to tirzepatide (Zepbound), Eli Lilly's Zepbound Savings Card can bring costs to as low as $550/month for commercially insured patients, and Novo Nordisk's savings program for Wegovy similarly offers reductions. Texas Medicaid (STAR/CHIP) generally does not cover GLP-1 agonists for weight loss without a diabetes diagnosis as of this publication date. Houston patients should work with their clinic's insurance coordinator, many clinics in Sugar Land and The Woodlands have dedicated staff for prior authorizations, and confirm coverage before interpreting a plateau as a reason to discontinue. Stopping semaglutide abruptly, as STEP 4 showed, results in significant weight regain.

Twelve or more weeks at semaglutide 2.4 mg with less than 5% additional weight loss, despite optimized diet and behavioral support, is the threshold Houston physicians use to flag a formal medication review. Three paths typically come up in that conversation: switching to tirzepatide (Zepbound), backed by SURMOUNT-1 and SURMOUNT-2 trial outcomes; adding bupropion/naltrexone (Contrave) for patients dealing with significant cravings or emotional eating; or a bariatric surgery referral for anyone with a BMI ≥40, or ≥35 with comorbidities.

Houston has three nationally accredited bariatric programs within reach of most Greater Houston residents. Houston Methodist Comprehensive Weight Management, UTHealth Houston Bariatric Center, and Memorial Hermann Bariatric & Metabolic Institute all handle cases where medication alone has stopped moving the needle.

A plateau on semaglutide sometimes means your degree of obesity requires a higher level of intervention. That's not a personal failure, and it's not a drug failure either. It's the treatment pathway doing exactly what it was designed to do, escalating care to match need.

Board-certified physicians in obesity medicine, endocrinology, or internal medicine with a dedicated weight management focus are your best option for managing a semaglutide plateau. Not every primary care provider has the training to handle what happens when your weight stops moving. The American Board of Obesity Medicine (ABOM) certifies physicians who have demonstrated expertise in the complex physiology of obesity and its treatment, including pharmacotherapy management.

The Houston Weight Loss Directory lists physician-supervised clinics across Harris County and its suburbs, including Katy, Sugar Land, The Woodlands, Pearland, and Cypress, that employ ABOM-certified or obesity-medicine-trained physicians. When you evaluate a clinic, ask four specific questions. Does the physician review metabolic labs, thyroid, fasting insulin, cortisol, when a plateau occurs? Is a registered dietitian part of the care team? Is behavioral health support offered or referred? Does the practice have experience transitioning patients between GLP-1 agents?

Those four questions draw a hard line between obesity medicine practices and clinics that simply write prescriptions and send you home. The answers matter most precisely when your weight has stalled.